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Directed activation of the immune system has become an increasingly feasible and effective option 
for cancer treatment. Normally, cytotoxic CD8 T-cells are activated to lyse target cells by the T-cell 
receptor binding small protein fragments (antigens) presented at the cell surface by major 
histocompatibility (MHC) molecules. For adoptive immunotherapy, T-cells are genetically engineered 
with receptors that recognize specific antigen-MHC molecules present on cancer cells. These 
modified T-cells are then expanded ex vivo and transferred back into patients to eradicate tumors. 
Adoptive T-cell therapy against the antigen NY-ESO-1 has shown great promise in preclinical 
models and in early stage clinical trials. Unfortunately, some tumors persist or relapse after therapy. 
Dr. Zandra Klippel and colleagues in the Warren laboratory in the Clinical Research Division 
examined NY-ESO-1-specific T-cell therapy in a mouse model of multiple myeloma. As reported in 
the journal Gene Therapy, the researchers demonstrate loss of heterozygosity at the MHC loci as 
one mechanism of immune evasion for tumors that fail therapy. 
In the current study, Dr. Klippel and colleagues examined adoptive T cell therapy against multiple 
myeloma. Multiple myeloma is the second most common blood cancer diagnosed in the United 
States and has thus far been incurable. The researchers reprogrammed CD8 T cells from multiple 
myeloma patients with a T-cell receptor specific to the antigen NY-ESO-1 and a particular MHC 
subtype called HLA-A2. NY-ESO-1 belongs to a set of cancer-testis antigens, whose expression is 
limited to human germ line cells in the testis and in various types of human cancers, making them 
ideal cancer antigens for tumor immunotherapy. The reprogrammed T-cells effectively recognized 
and destroyed multiple myeloma cells  that expressed NY-ESO-1 in complex with HLA-A2 in vitro. 
The researchers then transferred these reprogrammed T cells in a mouse model of multiple 
myeloma and observed potent antitumor activity in four of six mice (see figure).  
The authors examined the tumors of the two mice that failed adoptive T-cell therapy to understand 
the mechanism of immune escape. Therapy failure could be due to a number of potential 
mechanisms, including the lack of T cell persistence, the loss of antigen or MHC expression, the 
inability of T cells to migrate to the tumor, or the inhibition of T-cell function after infusion. The  
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researchers found comparable mRNA levels of the antigen NY-ESO-1 in the control and therapy-
resistant tumors. However, when the researchers examined the tumor cells by flow cytometry, they 
saw complete loss of cell surface HLA-A2 in therapy-resistant tumors. 
Next, Klippel et al. asked if the loss of MHC expression was at the genomic level and performed loss 
of heterozygosity (LOH) analysis on the tumor cells derived from control and resistant mice. The 
researchers observed LOH at three MHC loci in myeloma cells from one resistant mouse and at five 
loci in the other mouse. Although the genomic events were not identical in the two resistant mice, 
both involved loss of the HLA-A*02 allele, which is necessary to display the antigen NY-ESO-1 on 
the cell surface. The researchers confirmed these results by HLA-typing the resistant tumor cells by 
PCR. 
Other preclinical and clinical studies of NY-ESO-1-specific T-cell therapy for sarcoma, melanoma, 
and multiple myeloma have reported similar results: antitumor activity in some patients but failure in 
others. The mechanism of resistance was not examined in any of these studies, but the results of 
Klippel et al. suggest loss of MHC may be involved. The authors caution their results are derived 
from a genetically unstable multiple myeloma cell line; however, cancer cells display genomic 
instability as well. Overall, the results of this study demonstrate that LOH of MHC should be 
examined as an immune escape mechanism in patients who fail adoptive NY-ESO-1-specific T-cell 
therapy in current clinical trials. To overcome this immune evasion mechanism, an alternative 
approach for adoptive T-cell therapy is to genetically modify T cells to recognize molecules on 
cancer cells without relying on MHC presentation using chimeric antigen receptors (CARs). 
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Image modified from Klippel, et al. 2014 
T cells can be redirected to selectively kill cancer cells by introducing T-cell receptors that recognize 
specific cancer cell antigens in complex with MHC. Adoptive transfer of reprogrammed NY-ESO-1-
specific T-cells exhibits potent antitumor activity in some but not all xenografts of multiple myeloma 
in mice, suggesting immune escape mechanisms in the cancer cells. 
 
